References
- Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA298(17), 2038–2047 (2007).
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med.351(13), 1296–1305 (2004).
- Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med.353(3), 238–248 (2005).
- Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med.360(14), 1395–1407 (2009).
- Curhan GC. Prediabetes, prehypertension … is it time for pre-CKD? Clin. J. Am. Soc. Nephrol.5(4), 557–559 (2010).
- Farrow EG, White KE. Recent advances in renal phosphate handling. Nat. Rev. Nephrol.6(4), 207–217 (2010).
- Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J. Am. Soc. Nephrol.21(9), 1427–1435 (2010).
- Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Intern. Med.167(9), 879–885 (2007).
- Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J.156(3), 556–563 (2008).
- Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J. Am. Soc. Nephrol.20(2), 397–404 (2009).
- Eller P, Eller K, Kirsch AH et al. A murine model of phosphate nephropathy. Am. J. Pathol.178(5), 1999–2006 (2011).
- Watanabe R, Lemos MM, Manfredi SR, Draibe SA, Canziani ME. Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up. Clin. J. Am. Soc. Nephrol.5(2), 189–194 (2010).
- Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med.359(6), 584–592 (2008).
- Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J. Am. Soc. Nephrol.18(9), 2600–2608 (2007).
- Titan SM, Zatz R, Graciolli FG et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin. J. Am. Soc. Nephrol.6(2), 241–247 (2011).
- Evenepoel P, Meijers B, Viaene L et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol.5(7), 1268–1276 (2010).
- Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation119(19), 2545–2552 (2009).
- Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis205(2), 385–390 (2009).
- Jean G, Bresson E, Terrat JC et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol. Dial. Transplant.24(3), 948–955 (2009).